KRAS and colorectal carcinoma: A recent molecular subtype analysis of CRC patients showed that the “type 5” group (MSI-high, BRAF-and KRAS-mutation negative, non-CpG isl and methylator phenotype) was present in a significant portion of patients aged < 40 years and 40–49 years (10% and 20%, respectively) [29].